Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pol J Pathol ; 65(2): 135-40, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25119174

RESUMO

Most patients with gastric cancer are diagnosed at advanced clinical stages with a high frequency of lymph node metastasis. It is very important to find novel factors for the early diagnostic and prognostic evaluation of gastric cancer. It has been shown that IGF-1R activates mitotic division and inhibits apoptosis of cancer cells through the activation of signaling MAP/ERK and PI3K/Akt-1 pathways. IGF-1R plays a role in cell transformation and maintenance of the phenotype in modified cells. Moreover, an IGF-1 receptor effect influences the processes of adhesion, migration, invasion and metastasis of tumor cells. The aim of the study was to assess the expression of IGF-1R in gastric carcinoma in correlation with selected anatomo-clinical parameters. The study enrolled a group of 49 patients treated surgically for gastric cancer. 28 patients had no lymph node metastases. The expression of the studied proteins was assessed using the immunohistochemical method. We found that the expression of IGF-1R in gastric cancer is associated with lymph node metastasis (p < 0.001), is correlated with worse prognosis and high histological malignancy grade, and is an independent predictor of survival in patients with gastric cancer (p < 0.001). IGF-1R may play an important role in tumor growth and metastasis via the lymphatic pathway.


Assuntos
Biomarcadores Tumorais/análise , Carcinoma/química , Carcinoma/secundário , Receptor IGF Tipo 1/análise , Neoplasias Gástricas/química , Neoplasias Gástricas/patologia , Idoso , Biópsia , Carcinoma/mortalidade , Feminino , Humanos , Imuno-Histoquímica , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Gradação de Tumores , Neoplasias Gástricas/mortalidade , Análise de Sobrevida
2.
Adv Med Sci ; 58(2): 221-6, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23729584

RESUMO

PURPOSE: We identify the expression of PRL-3 in primary endometrioid endometrial cancer and metastases in relation to the clinicopathological characteristics. MATERIAL/METHODS: The study involved 30 patients with type I endometrial cancer. Twelve of them were diagnosed with metastases in various localization of abdomen. The PRL-3 expression was evaluated on the basis of immunohistochemistry results by the use of monoclonal antibody anti-PRL3 clone 3B6. RESULTS: The intensity of PRL-3 expression in correlation with tumor stage was statistically significant (p = 0.024). The strongest reaction was noted in cases classified as a 1a and 1b stage defined by FIGO. The strength of PRL-3 expression is significantly associated with the degree of histological tumor grade (p = 0.035). CONCLUSIONS: The strong expression of PRL-3 in the primary tumor that was significantly correlated with the grade and clinical stage suggest that PTP4A3 participates in the process of endometrial carcinogenesis.


Assuntos
Carcinoma Endometrioide/enzimologia , Neoplasias do Endométrio/enzimologia , Proteínas de Neoplasias/metabolismo , Proteínas Tirosina Fosfatases/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticorpos Monoclonais/farmacologia , Carcinoma Endometrioide/secundário , Neoplasias do Endométrio/patologia , Feminino , Humanos , Imuno-Histoquímica , Linfonodos/enzimologia , Linfonodos/patologia , Metástase Linfática , Pessoa de Meia-Idade , Proteínas de Neoplasias/imunologia , Estadiamento de Neoplasias , Prognóstico , Proteínas Tirosina Fosfatases/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...